ASSESSMENT OF ADVANCED LIVER FIBROSIS RISK IN OLDER ADULTS WITH TYPE 2 DIABETES MELLITUS AND NON-ALCOHOLIC FATTY LIVER DISEASE
Main Article Content
Abstract
Background: Advanced liver fibrosis is a critical clinical issue in patients with type 2 diabetes mellitus (T2DM) and coexisting non-alcoholic fatty liver disease (NAFLD), particularly in the elderly population. Nevertheless, in Vietnam, research data specifically addressing this group remain scarce.
Objective: To assess the risk of advanced liver fibrosis using the FIB-4 score and to identify associated factors in older adults with type 2 diabetes mellitus and NAFLD.
Methods: A cross-sectional study was conducted at the Endocrinology Outpatient Clinic of Thong Nhat Hospital from September 2024 to June 2025, involving patients aged ≥60 years with type 2 diabetes mellitus and coexisting NAFLD.
Results: Among 355 patients evaluated for the risk of advanced liver fibrosis, 73.24% were classified as low risk, 20.00% as indeterminate risk, and 6.76% as high risk. Multivariate logistic regression analysis identified chronic kidney disease (OR = 2.78; 95% CI: 1.27–6.10; p = 0.011) and white blood cell count (OR = 0.73; 95% CI: 0.62–0.84; p < 0.001) as independent factors associated with the risk of advanced liver fibrosis.
Conclusion: In older adults with type 2 diabetes mellitus and NAFLD, a considerable proportion were classified as having indeterminate or high risk of advanced liver fibrosis. Chronic kidney disease and white blood cell count were identified as independent factors closely associated with the risk of advanced liver fibrosis in this population.
Keywords
advanced liver fibrosis, non-alcoholic fatty liver disease, type 2 diabetes, elderly
Article Details
References
2. Luo Y, Wang C, Zhang T, et al. Factors associated with liver fibrosis in Chinese patients with type 2 diabetes mellitus and non-alcoholic fatty liver disease. 2023:293-302.
3. Martínez-Ortega AJ, Piñar Gutiérrez A, Lara-Romero C, et al. Prevalence of non-alcoholic fatty liver disease (NAFLD) in a cohort of patients with type 2 diabetes: the PHIGNA-DM2 study. Nutricion hospitalaria. Oct 17 2022;39(5):1012-1018. Prevalencia de la hepatopatía grasa no alcohólica (HGNA) en una cohorte de pacientes con diabetes de tipo 2: el estudio PHIGNA-DM2. doi:10.20960/nh.03969
4. Tuong TTK, Tran DK, Phu PQT, et al. Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes: Evaluation of Hepatic Fibrosis and Steatosis Using Fibroscan. Diagnostics (Basel, Switzerland). Mar 14 2020;10(3)doi:10.3390/diagnostics10030159
5. Yamane R, Yoshioka K, Hayashi K, et al. Prevalence of nonalcoholic fatty liver disease and its association with age in patients with type 2 diabetes mellitus. World journal of hepatology. Jun 27 2022;14(6):1226-1234. doi:10.4254/wjh.v14.i6.1226
6. Bogdan RG, Boicean A, Anderco P, et al. From Liver to Kidney: The Overlooked Burden of Nonalcoholic Fatty Liver Disease in Chronic Kidney Disease. 2025;14(7):2486.
7. Hydes TJ, Kennedy OJ, Buchanan R, et al. The impact of non-alcoholic fatty liver disease and liver fibrosis on adverse clinical outcomes and mortality in patients with chronic kidney disease: a prospective cohort study using the UK Biobank. BMC Medicine. 2023/05/18 2023;21(1):185. doi:10.1186/s12916-023-02891-x